Bamet-UD2

Bamet-UD2 is a novel experimental small molecule that combines a bile acid (ursodeoxycholic acid, UDCA) with a platinum-based chemotherapeutic agent (cisplatin). It is classified as a bile acid-platinum derivative. The drug was designed to enhance the liver-targeting properties of platinum compounds and reduce systemic toxicity. Preclinical studies have shown that Bamet-UD2 exhibits strong antitumor activity, particularly against liver tumors such as hepatoblastoma and hepatocellular carcinoma, with marked hepatobiliary organotropism—meaning it preferentially accumulates in the liver. Compared to conventional cisplatin, Bamet-UD2 demonstrates reduced nephrotoxicity, neurotoxicity, and bone marrow toxicity while maintaining or enhancing cytostatic effects on tumor cells[1][2][4][5][8]. Its mechanism of action involves DNA crosslinking via its platinum moiety (as with other platinum drugs), leading to inhibition of DNA replication and cell death in rapidly dividing tumor cells.

Other names

cis-diammine-bis-ursodeoxycholic platinum(II)cisplatin-ursodeoxycholate derivative